Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Blue chips lose early shine as US treads water

Mon, 03rd Jul 2023 17:05

(Alliance News) - London's FTSE 100 ran out of steam on Monday to close little changed, while New York markets made a muted start to an abbreviated session ahead of Independence Day.

Miners remained in favour on hope for economic stimulus in China, but AstraZeneca tumbled on concerns that a new lung cancer drug may not be as successful as had been hoped.

"It's been a bit of a snoozy start to July for European markets with an initially positive European open giving way to a more mixed session, with US markets only opening for a short time ahead of the US Independence Day holiday," CMC Markets analyst Michael Hewson commented.

The FTSE 100 index fell 4.27 points, 0.1%, at 7,527.26 well below its intraday high of 7,561.26. The FTSE 250 ended up 91.01 points, 0.5%, at 18,507.77. The AIM All-Share edged up 0.80 points, 0.1%, to 754.31.

The Cboe UK 100 was down 0.1% at 750.82, the Cboe UK 250 was up 0.6% at 16,192.78, though the Cboe Small Companies fell 0.4% to 13,661.36.

In European equities, the CAC 40 in Paris closed down 0.2% while the DAX 40 in Frankfurt fell 0.4%.

US markets made a subdued start after two manufacturing surveys showed the sector continued to weaken. The Dow Jones Industrial Average rose 0.1%, the S&P 500 was flat, while the Nasdaq Composite eased 0.1%.

Financial markets in New York close early at 1800 BST on Monday, 1pm local time, and remain closed on Tuesday for the Independence Day holiday.

S&P Global's purchasing managers' index reading fell to 46.3 points in June, from 48.4 in May, sinking further below the 50.0 neutral mark.

The Institute for Supply Management's PMI also made for a grim read, falling to 46.0 points in June, from 46.9 in May.

Shares in Tesla jumped 5.9% after investors welcomed a strong production update over the weekend, with car deliveries beating expectations.

In the second quarter, the electric-vehicle maker reported deliveries of 466,140 vehicles, an increase of 83% on a year before. The total was also ahead of analyst forecasts of 450,000.

As competition in the EV sector heats up, Tesla has made several price cuts in the US, Europe and Asia this year. The move has also allowed it to weather declining demand in China.

It is a gamble that "appears to be paying off handsomely", argued Hargreaves Lansdown's Susannah Streeter.

Limiting gains in London were comments from incoming Bank of England policymaker Megan Greene who warned of the dangers of complacency in the fight against inflation hinting she might back more interest rates rise in the UK.

"It would be a mistake for central bankers to take comfort in the notion that inflation and rates will automatically go back to the low levels we saw before the pandemic," she wrote in an article in the Financial Times. "This is their challenge for the future."

Mining stocks rallied on hopes of a stimulus in China. The Chinese manufacturing sector saw a softer rise in production last month, according to survey data.

The Caixin manufacturing purchasing managers' index eased to 50.5 points from 50.9 in May, coming in slightly higher than a flash estimate of 50.2.

"Now some of the disappointment about a slower than expected post-Covid recovery has eased, the focus is turning to potential financial stimulus and support, which could have positive implications for metals and energy demand," AJ Bell analyst Russ Mould commented.

Anglo American and Glencore took the top two places in the FTSE 100 risers list, up 4.1% and 3.3%, respectively.

Oil prices received a lift from output cuts by Russia and Saudi Arabia. Brent oil was trading at USD75.92 a barrel at the London close Monday, up from USD75.58. It had spiked as high as USD76.55 in morning trade.

Saudi Arabia announced it was extending a voluntary oil production cut of one million barrels per day, in a bid to prop up slumping prices. The cut which first took effect in July will continue in August and "can be extended", the official Saudi Press Agency reported, citing an energy ministry source.

Russia's top energy official, meanwhile, said that Moscow will voluntarily cut oil exports by 500,000 barrels per day, building on previously announced production cuts.

Alexander Novak said the move is to ensure "the oil market remains balanced".

Shares in BP rose 2.9%, Shell 1.6% and Harbour Energy 4.1%.

Sterling was quoted at USD1.2675 at the time of the London equities close on Monday, down from USD1.2706 on Friday. The euro traded at USD1.0905 down from USD1.0916. Against the yen, the dollar was quoted at JPY144.59, little changed from JPY144.58.

The downturn in the UK's manufacturing sector continued in June. The S&P Global/CIPS manufacturing PMI worsened to a six-month low of 46.5 points in June from 47.1 in May.

In the eurozone, the Hamburg Commercial Bank manufacturing PMI fell to 43.4 points in June from 44.8 in May, its lowest level since May 2020.

Back in London, AstraZeneca shares slumped 8.0% after results from a trial of its Dato-DXd lung cancer drug disappointed.

AstraZeneca is working with Tokyo-listed Daiichi Sankyo, who it has also collaborated with for the Enhertu drug.

In patients will locally advanced or metastatic non-small cell lung cancer treated with at last one prior therapy, Dato-DXd demonstrated a "statistically significant" improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy.

However, for the dual primary endpoint of overall survival, the data "were not mature".

"An early trend was observed in favour of [Dato-DXd] versus docetaxel that did not meet the prespecified threshold for statistical significance at this interim analysis," AstraZeneca said.

Analysts at Jefferies said the results seem "likely to fall short of best case."

"Limited detail, as expected, with results said to provide 'compelling evidence', suggesting a less pronounced benefit than hoped, in our view, plus 'some' Grade 5 ILD related deaths," the investment bank noted.

Gold was quoted at USD1,927.00 at the London close Monday, up from USD1,915.48 late Friday.

Oanda analyst Craig Erlam commented: "Gold has struggled in recent weeks against the backdrop of persistent stubborn inflation, resilient economic data, and, as a result, higher interest rate expectations. We're seeing it bounce back a little over the last couple of sessions after briefly dipping below USD1,900 but the trend is still very much against it."

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.